Indian regulator welcomes US FDA co-operation
This article was originally published in Clinica
Executive Summary
Surinder Singh, the head of India’s drug and medical device regulatory body has welcomed input from the US FDA, which earlier this year agreed with the country’s health ministry to collaborate on setting up a US style regulatory system for India (see Clinica Nos 1294, p 13 & 1303, p 10). Dr Singh highlighted medical devices and clinical trials as priority areas for US help, according to the Press Trust of India. Both areas are in need of greater comprehensiveness. Historically, the government has limited its role in clinical trials to the provision of licences and the scrutinising of data; and medical device regulations are currently under development, with legislation to establish a new centralised regulatory body awaiting approval from parliament. Three other areas will also receive input from US FDA advisors, according to Dr Singh: new drugs; pharmacology; healthcare IT; and IT-enabled services in the healthcare setting.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.